trimetazidine / Generic mfg. - LARVOL DELTA

TACT-TTR: Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Fábio Fernandes

New P2 trial • Amyloidosis • Cardiac Amyloidosis • Cardiovascular

Trimetazidine combined with metoprolol improves therapeutic outcomes in patients with coronary heart disease complicated by heart failure. (PubMed, Am J Transl Res) - "Trimetazidine combined with metoprolol demonstrates superior efficacy without increasing adverse reactions in CHD patients complicated by HF. This combination therapy may improve hemodynamic status, endothelial function, and cardiac function, supporting its clinical application."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Heart Failure • Metabolic Disorders

Design, Synthesis and Molecular Docking Studies of Some Novel Hydrazone Derivatives Based on Trimetazidine as Selective and Potent AChE Inhibitors. (PubMed, Drug Dev Res) - "The compounds were evaluated for in vitro inhibition of AChE and butyrylcholinesterase (BChE) using donepezil and tacrine as reference inhibitors, respectively. To rationalize the observed activity trends, molecular docking studies were performed, suggesting that the most active ligands adopt donepezil-like binding modes spanning the catalytic and peripheral anionic sites and are further stabilized by π-π/π-cation contacts and hydrogen-bonding interactions within the active gorge. Overall, these findings identify trimetazidine-derived hydrazide-hydrazones as a promising chemotype for the development of selective AChE inhibitors and provide a basis for further optimization and advanced biological validation."

Journal • Alzheimer's Disease • CNS Disorders • Pain

Use of toenail clippings to document an anti-doping violation. Evidence after trimetazidine contamination, trimetazidine single administration and trimetazidine therapeutic treatment. (PubMed, Clin Chem Lab Med) - No abstract available

Journal

Prophylactic ranolazine and trimetazidine attenuate right ventricular dysfunction and improve exercise capacity in experimental pulmonary hypertension (ESC 2026) - "Ranolazine additionally prevented adverse electrical remodeling. These findings support early metabolic intervention as a potential therapeutic strategy in PAH and warrant further clinical investigation."

Cardiovascular • Heart Failure

Effect of Trimetazidine on Endothelin-1 and Clinical Outcomes of Patients With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Sara Refaat Azab Metry

New P1/2 trial • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain • EDN1

Effects of QiShenYiQi dropping pills on gut dysbiosis and statin-associated muscle symptoms in ApoE-/- mice with type 2 diabetes mellitus and coronary heart disease. (PubMed, Front Cell Dev Biol) - "The mice were randomly divided into normal control (NC), disease model (DM), Simvastatin + Fenofibrate (SF), Simvastatin + Fenofibrate + QSYQ (SFQ), and Simvastatin + Fenofibrate + Trimetazidine (SFT) groups, with 90 days of intervention. These beneficial effects may be correlated to the regulation of gut microbiota, glycolipid metabolites and associated gene expression, including inflammation-related genes, apoptosis-related genes, as well as antioxidant and energy metabolism-related genes. These findings suggested the potential value of QSYQ as a promising candidate for T2DM and CHD, attenuating the side effects of statins, providing a novel complementary strategy for clinical treatment."

Journal • Preclinical • Cardiovascular • Coronary Artery Disease • Diabetes • Gastrointestinal Disorder • Heart Failure • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus • APOE

Targeting a novel metabolic vulnerability of non-small cell lung cancer to fatty acid oxidation surmounts chemoresistance. (PubMed, Drug Resist Updat) - "Increased LAP:LIP ratio induced chemoresistance in NSCLC tumors by instigating a FAO-dependence, unveiling a metabolic vulnerability. FAO inhibition emerges as a novel chemosensitization strategy operating via rewiring tumor and TIME metabolism."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ABCB1 • ABCC1 • ABCC2 • CD34 • CPT1A

A 46-Year-Old Man Presenting With Chest Pain Due to Apical Hypertrophic Cardiomyopathy (Yamaguchi Syndrome) Diagnosed by Multimodal Cardiac Imaging. (PubMed, Am J Case Rep) - "The patient's symptoms improved significantly with medical therapy, including losartan, metoprolol, and trimetazidine. CONCLUSIONS This case highlights the critical diagnostic challenge of ApHCM masquerading as ACS. It underscores the indispensable role of a multimodal imaging approach-integrating ECG, TTE, CCTA, and CMR-for an accurate diagnosis, particularly for identifying underlying myocardial fibrosis and guiding appropriate patient management."

Journal • Acute Coronary Syndrome • Cardiomyopathy • Cardiovascular • CNS Disorders • Depression • Fibrosis • Hypertrophic Cardiomyopathy • Immunology • Myocardial Infarction • Pain • Psychiatry

Potential Mechanisms of Trimetazidine and Coenzyme Q10 Against Antipsychotic-Induced Myocarditis: A Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation Study. (PubMed, CNS Neurosci Ther) - "Network pharmacology, molecular docking, and molecular dynamics simulations were used to investigate the potential pharmacological mechanisms underlying the effects of TMZ and CoQ10 in antipsychotic-induced myocarditis. The findings provide theoretical and computational evidence for future experimental studies on TMZ and CoQ10 as potential adjunctive therapeutic candidates for antipsychotic-induced myocarditis."

Journal • Cardiovascular • CNS Disorders • Inflammation • CASP3 • HIF1A • MMP9 • STAT3

TRI-ME: Trimetazidine to treat Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A double-blind, randomised, placebo-controlled efficacy trial (ANZCTR) - P2/3 | N=290 | Recruiting | Sponsor: Deakin University | N=126 ➔ 290

Enrollment change • CNS Disorders • Fatigue • Infectious Disease

Intermediate accumulated upon interruption of fatty acid oxidation flux promotes tumoral ferroptosis and improves immunotherapy. (PubMed, Nat Commun) - "Trimetazidine, an approved anti-ischemic drug and HADHA inhibitor, similarly delays tumor progression and augments immunotherapy. Together, our findings identify HADHA as a ferroptosis regulator and offer a clinically actionable strategy to enhance ferroptosis and immunotherapy through metabolic intervention."

Journal • Lung Cancer • Oncology • Solid Tumor

Efficacy of primary cardioprotection with perindopril, bisoprolol, and trimetazidine in high-risk patients with breast and gastric cancer receiving anthracycline- and trastuzumab-containing therapy. (ASCO 2026) - "AC (doxorubicin/cyclophosphamide) regimen was administered in 54 BC patients, AC followed by T in 30 BC pts, T – in 8 GC pts. In high-risk pts with BC and GC receiving anthracycline- and trastuzumab-containing therapy, primary CPT with perindopril, bisoprolol, and trimetazidine effectively prevents adverse cardiac remodeling, preserves myocardial systolic function, reduces the incidence of cardiovascular complications, and is associated with a significant reduction in one-year all-cause mortality."

Clinical • Breast Cancer • Congestive Heart Failure • Coronary Artery Disease • Gastric Cancer • Heart Failure • Oncology • Solid Tumor

A translational mechanistic synthesis of ischemia-reperfusion injury in experimental flap models toward free flap salvage. (PubMed, Front Surg) - "In a comparable severe ischemia epigastric island flap paradigm, trimetazidine, propionyl-L-carnitine, and lutein each demonstrated improved survival area relative to ischemic controls within their respective experimental contexts...These findings establish a translational mechanistic framework to guide rational adjunctive strategies in high-risk free flap protocols and support prospective clinical integration in microsurgical salvage scenarios. This synthesis is intended to guide mechanistic prioritization rather than imply direct interventional equivalence across models."

Journal • Review • Cardiovascular • Inflammation • Reperfusion Injury

Microvascular Dysfunction in Ischemia with No Obstructive Coronary Arteries (INOCA): Pathophysiology, Diagnosis, and Emerging Therapies. (PubMed, Cardiovasc Hematol Disord Drug Targets) - "INOCA includes several types linked to small vessel problems and spasms, which should be identified using specific tests. Treating patients according to their INOCA type leads to better outcomes."

Journal • Cardiovascular • Inflammation

Ferroptosis: key regulatory pathways and their implications in cardiovascular pathophysiology. (PubMed, Front Cardiovasc Med) - "Furthermore, emerging therapeutic strategies targeting ferroptosis, including iron chelators, lipid peroxidation inhibitors, and metabolic modulators (e.g., metformin, trimetazidine), are discussed for their potential to mitigate cardiovascular damage. By bridging molecular mechanisms (enhanced by spatial metabolomics insights) to clinical applications, this review underscores ferroptosis as a promising therapeutic target, advocating for further research to translate these insights into precision interventions for CVD management."

Journal • Review • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • Metabolic Disorders • Reperfusion Injury • AMPK • GPX4

Trimetazidine's Anti-ischemic Effectiveness in Patients with Stable Angina with Prior Myocardial Infarction Evaluated via Stress Echocardiography with Speckle Tracking: METHOD study. (PubMed, Cardiol Ther) - P | "This real-world study supports TMZ OD role as a valuable adjunct to standard antianginal therapy in outpatients with stable CAD and a history of MI."

Journal • Cardiovascular • Coronary Artery Disease • Mood Disorders • Myocardial Infarction • Myocardial Ischemia • Pain • Psychiatry

Systematic review and meta-analysis of clinical trials on the efficacy and safety of trimetazidine in patients with heart failure (HEART FAILURE 2026) - No abstract available

Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

An international, double-blind, randomized, placebo-controlled clinical trial of adjunctive trimetazidine to treat people with bipolar depression (the TIDE trial) protocol. (PubMed, BMC Psychiatry) - No abstract available

Clinical • Journal • Bipolar Disorder • CNS Disorders • Depression • Inflammation • Mood Disorders • Psychiatry

The hypothalamus is an early site of mitochondrial failure and neuro-immune circuit disruption in amyotrophic lateral sclerosis. (PubMed, Mol Metab) - "These findings establish the hypothalamus as an early and selectively vulnerable site in ALS, where region-specific mitochondrial dysfunction contributes to metabolic and neuroinflammatory alterations. Targeting hypothalamic bioenergetics represents a promising therapeutic strategy."

Journal • Amyotrophic Lateral Sclerosis • CNS Disorders • Inflammation • Metabolic Disorders

SYSTEMATIC REVIEW OF PHARMACOLOGIC THERAPIES FOR NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (ACC 2026) - "Cardiac myosin inhibitors (CMIs) lowered pro-brain natriuretic peptide and troponin, improved diastolic indices, and induced modest left ventricular remodeling; aficamten improved functional status in contrast to mavacamten...Renin-angiotensin-aldosterone system (RAAS) agents were largely neutral, but valsartan improved a composite remodeling score in early nHCM. Metabolic modulators were inconsistent - perhexiline and ninerafaxstat showed some benefits, while ranolazine and trimetazidine did not. CMIs show the most consistent efficacy, followed by SGLT2is and cibenzoline; RAAS agents and metabolic modulators provide variable or limited benefit. Further trials are needed to clarify the role of SGLT2is and CMIs in nHCM."

Review • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Personalized management of angina and heart failure in clinical practice in the Middle East: a narrative review. (PubMed, J Comp Eff Res) - "Clinicians should consider adding newer antianginal agents (long-acting nitrates, ranolazine, trimetazidine, ivabradine) to beta-blockers + calcium-channel blockers based on patient risk factors. In patients with HF with reduced ejection fraction in sinus rhythm and elevated heart rate, ivabradine should be added to maximum tolerated doses of beta-blockers. Adding ivabradine to first-line therapy improves heart rate control and QoL, and reduces HF-related hospitalization and mortality."

Journal • Review • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction

Metabolic Adaptation of CD8⁺ T Cells Limits the Efficacy of Fatty Acid Oxidation Inhibition in Type 1 Diabetes. (PubMed, Int J Biol Sci) - "We investigated whether the fatty acid oxidation (FAO) inhibitor trimetazidine (TMZ), one of only three approved drugs directly targeting cellular metabolism, can restrain autoreactive immunity and delay T1D in non-obese diabetic mice (NOD)...The adaptive upregulation of CPT1A demonstrates a novel evasion mechanism to FAO inhibition and underscores the central role of FAO in sustaining pathogenic T cells. Our work highlights metabolic adaptation as a key determinant of autoimmune progression, validating FAO as a therapeutic target in T1D."

Journal • Diabetes • Immunology • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • CD4 • CD8 • CPT1A

Jinxinkang Granule Preserves Myocardial Function by Suppressing Cardiac Senescence Through the cGAS-STING Axis in a Pressure Overload Mouse Model of Heart Failure. (PubMed, Cardiovasc Toxicol) - "Animals were randomized into control, model, JXK (low, medium, high dose), or positive control (trimetazidine) groups...Mechanistically, JXK suppressed TAC-induced upregulation of p16, p53, and MMP3, and inhibited cGAS, STING, p-TBK1, and p-IRF3 activation. JXK preserves cardiac function and attenuates remodeling in pressure overload-induced HF, potentially through inhibition of myocardial senescence and suppression of the cGAS-STING pathway."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • MMP3 • STING

Inhibiting Fatty Acid Oxidation With a Mitotrope in Heart Failure With Preserved Ejection Fraction. (PubMed, Circulation) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure